The phase 3 Clinical Assessment of phaRmacokinetics, Efficacy, Safety of a 10% Ig (CARES10) study was designed to evaluate the safety, efficacy, and pharmacokinetics of a 10% intravenous immunoglobulin in 47 patients with primary immunodeficiency. The primary efficacy end point was to investigate the incidence rate of acute serious bacterial infections per patient-year. Secondary end points included laboratory, clinical, and health-related quality of life measures.

Learn more by clicking here.